Avita Medical Inc. (RCEL) vs Relmada Therapeutics, Inc. (RLMD)

A side-by-side comparison of Avita Medical Inc. and Relmada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — RCEL vs RLMD

growth of $100 · dividends reinvested · last 10y
RCEL +44.8% (+3.8%/yr)RLMD +231.4% (+12.7%/yr)RLMD compounded faster over this window
02004006008001kStart $10020182020202220242026$145$331
RCEL RLMD

RCEL vs RLMD: by the numbers

  • •RLMD is the larger company ($348M vs $320M market cap).
  • •Both run net losses; RLMD's is the smaller (0.00% vs -56.96% net margin).

Metrics side by side

Valuation

MetricRCELRLMD
P/S ratio4.23N/A
P/B ratioN/A1.69

Profitability

MetricRCELRLMD
Gross margin81.56%0.00%
Operating margin-59.40%0.00%
Net margin-56.96%0.00%
ROEN/A-29.98%
ROIC-136.92%-30.78%

Growth (annualized)

MetricRCELRLMD
Revenue CAGR (5Y)20.94%N/A
Total return CAGR (5Y)-5.28%-7.68%

Frequently asked

How have RCEL and RLMD total returns compared?
Over the past 10 years, RCEL delivered 4.36% and RLMD delivered 12.41% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.